DelveInsight’s, “Chronic Urticaria Pipeline Insight 2023” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in the Chronic Urticaria pipeline landscape. It covers the Chronic Urticaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Urticaria pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Chronic Urticaria Pipeline Report
- DelveInsight’s Chronic Urticaria pipeline report depicts a robust space with 22+ active players working to develop 22+ pipeline therapies for Chronic Urticaria treatment.
- The leading companies working in the Chronic Urticaria Market include Novartis, Synermore Biologics, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Celltrion, United BioPharma, Glenmark Pharmaceuticals, UCB Biopharma, GI Innovation, Celldex Therapeutics, Eli Lilly and Company, Amgen, ValenzaBio, Third Harmonic Bio, Inmagene, Lanier Biotherapeutics, and others.
- Promising Chronic Urticaria Pipeline Therapies in the various stages of development include Omalizumab 75-375 mg, Loratadine, Clemastine, AK002, Levocetirizine, and others.
- September 2023: Sanofi announced a study of phase 3 clinical trials for Dupilumab SAR231893 and non-sedating H1-antihistamine. To demonstrate the efficacy of dupilumab in study participants with CSU who remain symptomatic despite the use of H1 antihistamine (Study A and C: omalizumab naïve; Study B: omalizumab intolerant or incomplete responders)
- September 2023: Novartis Pharmaceuticals announced a study of phase 3 clinical trials for LOU064 (blinded). The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 studies.
Request a sample and discover the recent advances in Chronic Urticaria Treatment Drugs @ Chronic Urticaria Pipeline Report
In the Chronic Urticaria pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Urticaria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Chronic Urticaria Overview
Chronic urticaria is defined as daily itchy wealing of the skin for more than six weeks. Chronic urticaria may be spontaneous or inducible, which may co-exist. Chronic urticaria can affect children and adults. Chronic inducible urticaria is more common than chronic spontaneous urticaria.
Find out more about Chronic Urticaria Therapeutics Assessment @ Chronic Urticaria Preclinical and Discovery Stage Products
Chronic Urticaria Emerging Drugs Profile
- Remibrutinib: Novartis
- SYN008: Synermore Biologics
Chronic Urticaria Pipeline Therapeutics Assessment
There are approx. 22+ key companies which are developing the Chronic Urticaria therapies. The Chronic Urticaria companies which have their Chronic Urticaria drug candidates in the most advanced stage, i.e. phase III include, Novartis.
Learn more about the emerging Chronic Urticaria Pipeline Therapies @ Chronic Urticaria Clinical Trials Assessment
Scope of the Chronic Urticaria Pipeline Report
- Coverage- Global
- Chronic Urticaria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Chronic Urticaria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Chronic Urticaria Companies- Novartis, Synermore Biologics, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Celltrion, United BioPharma, Glenmark Pharmaceuticals, UCB Biopharma, GI Innovation, Celldex Therapeutics, Eli Lilly and Company, Amgen, ValenzaBio, Third Harmonic Bio, Inmagene, Lanier Biotherapeutics, and others.
- Chronic Urticaria Pipeline Therapies- Omalizumab 75-375 mg, Loratadine, Clemastine, AK002, Levocetirizine, and others.
Dive deep into rich insights for new drugs for Chronic Urticaria Treatment, Visit @ Chronic Urticaria Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Chronic Urticaria: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Chronic Urticaria – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Remibrutinib: Novartis
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- GBR 310: Glenmark Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- UB-221: United BioPharma
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- IMG 036: Inmagene
- Drug profiles in the detailed report…..
- Inactive Products
- Chronic Urticaria Key Companies
- Chronic Urticaria Key Products
- Chronic Urticaria- Unmet Needs
- Chronic Urticaria- Market Drivers and Barriers
- Chronic Urticaria- Future Perspectives and Conclusion
- Chronic Urticaria Analyst Views
- Chronic Urticaria Key Companies
- Appendix
For further information on the Chronic Urticaria Pipeline therapeutics, reach out to Chronic Urticaria Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking
